# Study Evaluating Changes In Mammographic Breast Density

> **NCT00774267** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 507 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** BZA 20 mg/CE 0.45 mg
- **DRUG:** BZA 20 mg/CE 0.625 mg
- **DRUG:** Raloxifene 60 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00774267
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2014-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774267, "Study Evaluating Changes In Mammographic Breast Density". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00774267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*